

EMLc

Codes ATC: J01DD01

Indication	Other specified pneumonia	Code ICD11: CA40.Y
INN	Cefotaxime	
Type de médicament	Chemical agent	
Groupes d'antibiotiques	 WATCH	
Type de liste	Liste de base (EML) (EMLc)	
Additional notes	3rd generation cephalosporin of choice for use in hospitalized neonates.	
Formulations	Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt) ; 500 mg in vial powder for injection (as sodium salt) ; 1 g in vial powder for injection (as sodium salt) ; 2 g in vial powder for injection (as sodium salt)	
Historique des statuts LME	Ajouté pour la première fois en 2017 (TRS 1006) Modifié en 2023 (TRS 1049)	
Sexe	Tous	
Âge	Aussi recommandé pour les enfants	
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique	
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite <a href="#">sur les brevets</a> . 	
Wikipédia	<a href="#">Cefotaxime</a> 	
DrugBank	<a href="#">Cefotaxime</a> 	

### Recommandation du comité d'experts

The Expert Committee recommended the inclusion of a new strength, child-friendly dispersible tablet formulation of amoxicillin + clavulanic acid (200 mg + 28.5 mg) as an Access group antibiotic on the core list of the EMLc for treatment of bacterial infections in children – specifically those infections for which amoxicillin + clavulanic acid is already recommended on the EMLc. The Committee noted that the 7:1 ratio of amoxicillin to clavulanic acid is associated with similar efficacy to the 4:1 ratio but has a reduced frequency of gastrointestinal adverse effects. The Committee endorsed the importance of age-appropriate formulations to better meet the dosing needs of children. Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended:

- the addition of a new formulation of amoxicillin + clavulanic acid (dispersible tablet 250 mg + 62.5 mg) to the EMLc.
- the addition of new strength formulations of cefotaxime (powder for injection: 500 mg; 1 g; 2 g (as sodium) in vial) to the EML and EMLc.
- the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc.

### Recommandations de la LME : Other specified pneumonia

**Premier choix****Second choix****HOSPITAL-ACQUIRED PNEUMONIA**

piperacillin + tazobactam

amoxicillin + clavulanic acid

cefotaxime

ceftriaxone

